1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).

MLA

Riess, J. W., et al. “1038P A Phase II Trial of the IO102-IO103 Vaccine plus Pembrolizumab: Preliminary Analysis for First-Line (1L) Treatment of Non-Small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).” Annals of Oncology, vol. 34, Oct. 2023, p. S630. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2177.

APA

Riess, J. W., Cohen, E., Spicer, J., Shaw, P. H., Rubio Perez, J., Medina Rodríguez, L., Chaney, M. F., O’Neill, S., Pedersen, A. W., McDowell, D., Ehrnrooth, E., & Garrido Lopez, P. (2023). 1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology, 34, S630. https://doi.org/10.1016/j.annonc.2023.09.2177

Chicago

Riess, J.W., E. Cohen, J. Spicer, P.H. Shaw, J. Rubio Perez, L. Medina Rodríguez, M.F. Chaney, et al. 2023. “1038P A Phase II Trial of the IO102-IO103 Vaccine plus Pembrolizumab: Preliminary Analysis for First-Line (1L) Treatment of Non-Small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).” Annals of Oncology 34 (October): S630. doi:10.1016/j.annonc.2023.09.2177.